Explore the words cloud of the DermoSafe 2.0 project. It provides you a very rough idea of what is the project "DermoSafe 2.0" about.
The following table provides information about the project.
|Coordinator Country||Switzerland [CH]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2018-12-01 to 2019-03-31|
Take a look of project's partnership.
DermoSafe® is an integral platform based on DermoBrain, a cognitive computing system which will enable the early detection of skin cancer for broad population. The ICT-based approach facilitates and speeds the professional analysis of potential skin lesion by employing Dermoscopy Imaging. DermoSafe provides an accurate tool that allows patient performing the needed increased analysis to combat the exploded incidence of skin cancer without the requirement of an appointment with general practitioners or dermatologists, reducing lead time of the skin analysis results from 42 to 3 days. Hence, patient uncertainty and anxiety is clearly diminished. Furthermore, DermoSafe enables a fast and easy access to Dermoscopy experts to the healthcare professional community (pharmacies, general practitioners and dermatologists). DermoSafe has demonstrated capability to overpass the limitations posed by current Dermoscopy devices for early and broad screening by avoiding the need of a high investment to buy the equipment as well as offsets the lack of specialised dermatology workforce. Once implemented in the healthcare system and at pharmacies, DermoSafe can reduce the skin cancer budget up to 136,000€/patient. Since our platform and associated service will make the use of Dermoscopy imaging as broad as the use of a thermometer, the business opportunity seems unquestionable. The objective of this project is the further development of DermoBrain, to enable (1) skin lesion pattern recognition and identification for automatic history tracking and evolution rating, (2) automatic image quality check, and (3) image automatic classification considering also the patient medical context by artificial intelligence. By deploying DermoSafe platform in Europe, we aim to achieve a cumulative cash flow of 10.7 M€ by 2024, resulting in a ROI of 4.2
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DERMOSAFE 2.0" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "DERMOSAFE 2.0" are provided by the European Opendata Portal: CORDIS opendata.